Arecor Therapeutics PLC Ordinary Shares (AREC)

Industry Biotechnology


This stock can be held in an Investment ISA and an Investment Account
Sell

60.00p

Buy

65.00p

arrow-down-2.50p (-3.85%)

Prices updated at 12 Jun 2026, 17:13 BST
| Prices minimum 15 mins delay
|
Prices in GBX

Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platfo ...
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Andrew John McGlashan Richards CBE
CEO
Ms. Sarah Jennifer Howell
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
33
Head office
Chesterford Research Park
Saffron Walden
United Kingdom
CB10 1XL
mobile
+44 1223426060
letter
info@arecor.com

Key personnel

Salary
Dr. Andrew John McGlashan Richards CBE
Non-Executive Director, Chairman
-
Mr. Mohammad Sohail Fazeli
Non-Executive Director
-
Mr. Jeremy Lewis Morgan
Non-Executive Director
-
Mr. David Ellam
Executive Director, Chief Financial Officer and Company Secretary
-
Ms. Sarah Jennifer Howell
Executive Director, Chief Executive Officer
-

Top 5 shareholders

No. of shares
Unicorn Asset Management Ltd1,198,828
Unicorn AIM VCT Series 3 ORD1,198,828
Hargreave Hale Limited517,518
Calculus Capital Limited425,287
TM Oberon UK Special Situations Fund389,897

Director dealings

Action
No data
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2026 Morningstar. All rights reserved.